Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. Issue 12 (24th June 2019)

• Record Type: Journal Article
• Authors: Xu, Yiwang; Miremadi, Ahmad; Link, Alexander; Malfertheiner, Peter; Fitzgerald, Rebecca C; Bornschein, Jan
• Is Part Of: Journal of clinical pathology. Volume 72:Issue 12(2019)
• Page Start: 825
• Page End: 829
• Publication Date: 2019-06-24
• Subjects: pepsinogens -- TFF3 -- barrett's oesophagus -- gastric atrophy -- gastric cancer; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2019-205700
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Aims: Aim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy. Methods: Blood samples from 56 patients with Barrett's oesophagus and 202 non-Barrett controls who previously took part in a trial assessing the accuracy of the Cytosponge for Barrett's oesophagus were assessed for serum pepsinogen (PG) 1 and 2, gastrin-17, trefoil factor 3 (TFF3) and Helicobacter pylori infection. Results: PG1 was pathological (<50 ng/mL) in 26 patients (10.1%), none of whom had Barrett's oesophagus (p<0.001). Smoking and drinking had no influence on these results. Pathological PG1 was associated with stomach pain (p=0.029), disruption of sleep (p=0.027) and disruption of diet by symptoms (p=0.019). Serum TFF3 was not associated with any clinical parameter. Conclusions: Assessment of serum PG1 could be combined with a test for Barrett's oesophagus to identify additional patients requiring endoscopy.